Xilio Therapeutics, Inc. (XLO) Stock Forecast
XLO analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 1 analysts
- Price target
- $20.00 average of analyst targets
- Upside to target
- +133.9% from the latest close
- Next earnings
- November 12, 2026
- 52-week range
- $7.14 – $11.90
XLO analyst ratings
1 analystsNumber of analysts at each rating.
XLO price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
XLO earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.82 | −$0.82 | −$0.82 | −$1.54 | +46.8% | 1 |
| Current fiscal year (2026) | −$2.59 | −$2.59 | −$2.59 | −$4.19 | +38.2% | 1 |
| Next fiscal year (2027) | −$2.23 | −$2.23 | −$2.23 | −$2.59 | +13.9% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
XLO revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $4.8M | $4.8M | $4.8M | −74.6% | 1 |
| Current fiscal year (2026) | $40.3M | $40.3M | $40.3M | −7.8% | 1 |
| Next fiscal year (2027) | $26.5M | $26.5M | $26.5M | −34.2% | 1 |
XLO EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
XLO revenue: reported and forecast
XLO EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.92 | −$0.92 | −$0.92 | −$0.92 | −$0.82 | −10.9% | 1 up · 0 down |
| Current fiscal year (2026) | −$3.02 | −$3.02 | −$3.02 | −$3.02 | −$2.59 | −14.2% | 1 up · 0 down |
| Next fiscal year (2027) | −$2.59 | −$2.59 | −$2.59 | −$2.59 | −$2.23 | −13.9% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
XLO earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; XLO beat in 8 of 12.
What analysts expect from XLO
1 analysts cover Xilio Therapeutics; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $20.00, 133.9% above the latest close of $8.55. Analysts expect earnings of −$2.59 per share for 2026, +38.2% from a year earlier. For 2027 the average estimate is −$2.23 per share on revenue of $26.5 million. Xilio Therapeutics beat the EPS estimate in 8 of the last 12 quarters.
Related: XLO income statement, XLO key metrics, XLO chart. See the XLO stock overview for the latest quote and news.
XLO forecast FAQ
What is Xilio Therapeutics's price target?
The average analyst price target for Xilio Therapeutics is $20.00, 133.9% above the latest close of $8.55.
Is Xilio Therapeutics a buy, hold or sell?
Of 1 analysts covering Xilio Therapeutics, 1 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Xilio Therapeutics's EPS forecast?
Analysts forecast −$2.59 per share for 2026 (range −$2.59 to −$2.59); for 2027 the estimate is −$2.23.
What is Xilio Therapeutics's revenue forecast?
The average revenue estimate for 2026 is $40.3 million, growth of −7.8%; for 2027 it is $26.5 million.
When does Xilio Therapeutics report earnings?
Xilio Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 12, 2026.
Does Xilio Therapeutics usually beat earnings estimates?
Xilio Therapeutics reported EPS at or above the analyst estimate in 8 of the last 12 quarters.